vs
Side-by-side financial comparison of Invivyd, Inc. (IVVD) and Eightco Holdings Inc. (ORBS). Click either name above to swap in a different company.
Invivyd, Inc. is the larger business by last-quarter revenue ($17.2M vs $10.2M, roughly 1.7× Eightco Holdings Inc.). Invivyd, Inc. runs the higher net margin — -64.3% vs -2281.6%, a 2217.3% gap on every dollar of revenue. On growth, Invivyd, Inc. posted the faster year-over-year revenue change (24.5% vs -49.9%).
Invivyd, Inc. is a clinical-stage biopharmaceutical company focused on developing broadly neutralizing antibody therapies to prevent and treat serious viral infectious diseases. Its core research and development pipeline targets high-burden respiratory pathogens including respiratory syncytial virus, catering to unmet medical needs of global patient groups.
IVVD vs ORBS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $17.2M | $10.2M |
| Net Profit | $-11.1M | $-232.5M |
| Gross Margin | — | -13.0% |
| Operating Margin | -73.0% | -475.0% |
| Net Margin | -64.3% | -2281.6% |
| Revenue YoY | 24.5% | -49.9% |
| Net Profit YoY | 40.0% | -9183.3% |
| EPS (diluted) | $0.02 | $-2.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $17.2M | $10.2M | ||
| Q3 25 | $13.1M | $5.3M | ||
| Q2 25 | $11.8M | $7.6M | ||
| Q1 25 | $11.3M | $9.9M | ||
| Q4 24 | $13.8M | $20.3M | ||
| Q3 24 | $9.3M | $6.1M | ||
| Q2 24 | $2.3M | $5.3M | ||
| Q1 24 | $0 | $8.0M |
| Q4 25 | $-11.1M | $-232.5M | ||
| Q3 25 | $-10.5M | $-25.8M | ||
| Q2 25 | $-14.7M | $-1.2M | ||
| Q1 25 | $-16.3M | $-2.5M | ||
| Q4 24 | $-18.4M | $-2.5M | ||
| Q3 24 | $-60.7M | $-3.2M | ||
| Q2 24 | $-47.2M | $4.4M | ||
| Q1 24 | $-43.5M | $1.9M |
| Q4 25 | — | -13.0% | ||
| Q3 25 | — | -3.7% | ||
| Q2 25 | — | 16.4% | ||
| Q1 25 | — | 8.2% | ||
| Q4 24 | — | 8.2% | ||
| Q3 24 | — | 26.5% | ||
| Q2 24 | — | 25.1% | ||
| Q1 24 | — | 17.5% |
| Q4 25 | -73.0% | -475.0% | ||
| Q3 25 | -84.0% | -116.9% | ||
| Q2 25 | -127.8% | -15.9% | ||
| Q1 25 | -149.7% | -14.3% | ||
| Q4 24 | -139.1% | -11.9% | ||
| Q3 24 | -670.0% | -29.1% | ||
| Q2 24 | -2175.2% | -16.4% | ||
| Q1 24 | — | -39.6% |
| Q4 25 | -64.3% | -2281.6% | ||
| Q3 25 | -79.7% | -487.6% | ||
| Q2 25 | -124.4% | -15.4% | ||
| Q1 25 | -144.1% | -25.7% | ||
| Q4 24 | -133.5% | -12.3% | ||
| Q3 24 | -653.1% | -52.5% | ||
| Q2 24 | -2086.9% | 84.2% | ||
| Q1 24 | — | 24.4% |
| Q4 25 | $0.02 | $-2.34 | ||
| Q3 25 | $-0.06 | $-0.58 | ||
| Q2 25 | $-0.12 | $-0.38 | ||
| Q1 25 | $-0.14 | $-0.84 | ||
| Q4 24 | $-0.14 | $-1.44 | ||
| Q3 24 | $-0.51 | $-1.77 | ||
| Q2 24 | $-0.40 | $2.15 | ||
| Q1 24 | $-0.38 | $1.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $226.7M | $58.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $241.5M | $232.6M |
| Total Assets | $276.9M | $250.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $226.7M | $58.5M | ||
| Q3 25 | $85.0M | $23.7M | ||
| Q2 25 | $34.9M | $696.3K | ||
| Q1 25 | $48.1M | $434.4K | ||
| Q4 24 | $69.3M | $239.2K | ||
| Q3 24 | $106.9M | $2.4M | ||
| Q2 24 | $147.9M | $363.1K | ||
| Q1 24 | $189.4M | $808.8K |
| Q4 25 | $241.5M | $232.6M | ||
| Q3 25 | $93.1M | $339.2M | ||
| Q2 25 | $42.8M | $8.9M | ||
| Q1 25 | $54.1M | $9.7M | ||
| Q4 24 | $67.5M | $11.9M | ||
| Q3 24 | $83.2M | $13.0M | ||
| Q2 24 | $140.6M | $13.8M | ||
| Q1 24 | $178.5M | $3.9M |
| Q4 25 | $276.9M | $250.2M | ||
| Q3 25 | $139.2M | $355.5M | ||
| Q2 25 | $89.1M | $48.7M | ||
| Q1 25 | $103.7M | $47.6M | ||
| Q4 24 | $129.5M | $50.8M | ||
| Q3 24 | $161.9M | $49.2M | ||
| Q2 24 | $177.3M | $48.4M | ||
| Q1 24 | $215.5M | $50.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.5M | $-11.0M |
| Free Cash FlowOCF − Capex | — | $-11.0M |
| FCF MarginFCF / Revenue | — | -107.7% |
| Capex IntensityCapex / Revenue | 0.0% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-15.5M | $-11.0M | ||
| Q3 25 | $-8.3M | $-1.6M | ||
| Q2 25 | $-13.3M | $-659.2K | ||
| Q1 25 | $-21.1M | $999.8K | ||
| Q4 24 | $-37.6M | $-6.6M | ||
| Q3 24 | $-41.1M | $77.7K | ||
| Q2 24 | $-41.6M | $-440.3K | ||
| Q1 24 | $-50.2M | $-723.3K |
| Q4 25 | — | $-11.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | $-13.3M | $-661.3K | ||
| Q1 25 | $-21.3M | $999.7K | ||
| Q4 24 | $-37.6M | $-6.6M | ||
| Q3 24 | $-41.1M | $73.0K | ||
| Q2 24 | — | — | ||
| Q1 24 | $-50.4M | — |
| Q4 25 | — | -107.7% | ||
| Q3 25 | — | — | ||
| Q2 25 | -112.9% | -8.7% | ||
| Q1 25 | -188.2% | 10.1% | ||
| Q4 24 | -272.2% | -32.7% | ||
| Q3 24 | -441.6% | 1.2% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 0.0% | 0.0% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.1% | 0.0% | ||
| Q1 25 | 1.3% | 0.0% | ||
| Q4 24 | 0.0% | 0.0% | ||
| Q3 24 | 0.1% | 0.1% | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -0.10× | ||
| Q1 24 | — | -0.37× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
